<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586270</url>
  </required_header>
  <id_info>
    <org_study_id>TAS0612-101</org_study_id>
    <secondary_id>2020-002304-39</secondary_id>
    <nct_id>NCT04586270</nct_id>
  </id_info>
  <brief_title>A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer</brief_title>
  <official_title>A Phase 1 Study of TAS0612 in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if TAS0612 is safe in participants with advanced or&#xD;
      metastatic solid tumor cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 day cycle)</time_frame>
    <description>Number of participants with DLTs during cycle 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline through measured progressive disease (estimated up to 24 months)</time_frame>
    <description>Percentage of participants with partial response (PR) or complete response (CR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline through progressive disease (estimated up to 24 months)</time_frame>
    <description>DCR: Percentage of participants who exhibit stable disease (SD), PR or CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Estimated up to 22 months</time_frame>
    <description>DOR: Date of PR or CR to date of objective progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Estimated up to 24 months</time_frame>
    <description>Baseline to objective progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of TAS0612</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 day cycle)</time_frame>
    <description>Cmax of TAS0612</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): plasma concentration of TAS0612</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 day cycle)</time_frame>
    <description>Plasma concentration of TAS0612</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area under the plasma concentration curve (AUC)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 day cycle)</time_frame>
    <description>AUC of TAS0612</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time it takes to reach Cmax (Tmax) of TAS0612</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 day cycle)</time_frame>
    <description>Tmax of TAS0612</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time it takes for plasma concentration to fall by half its original value (t1/2) of TAS0612</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 day cycle)</time_frame>
    <description>t1/2 of TAS0612</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Estimated up to 24 months</time_frame>
    <description>All adverse events (AEs) per CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: biochemical effects of TAS0612</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28-day cycle)</time_frame>
    <description>Total proteins and phospho-proteins will be measured in blood samples collected at different time points. The levels/changes (dose- and concentration-dependent) of phospho-proteins will be assessed and reported for biochemical effects of TAS0612.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: molecular effects in tumor tissue of TAS0612</measure>
    <time_frame>Baseline through Day 1 Cycle 2 (28-day cycle)</time_frame>
    <description>Selected phospho-proteins will be analyzed in tumor tissue at baseline and on-treatment in dose escalation. The levels/changes of the phospho-proteins will be assessed and reported for target modulation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>TAS0612 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS0612 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS0612 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAS0612 administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS0612</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>TAS0612 Escalation</arm_group_label>
    <arm_group_label>TAS0612 Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dose Escalation: have evidence of a solid tumor that is locally advanced and/or&#xD;
             metastatic (excluding primary brain tumor)&#xD;
&#xD;
          -  Dose Expansion: have evidence of a solid tumor as outlined below that is locally&#xD;
             advanced and/or metastatic (excluding primary brain tumor)&#xD;
&#xD;
               -  Cohort A: Human epidermal growth factor negative (HER2 negative) Breast Cancer&#xD;
                  with an NF1 mutation&#xD;
&#xD;
               -  Cohort B: Hormone receptor positive (HR+)/HER2 negative breast cancer after&#xD;
                  progression on endocrine therapy and a CDK4/6 inhibitor&#xD;
&#xD;
               -  Cohort C: PTEN loss or mutations&#xD;
&#xD;
               -  Cohort D: KRAS G12C mutation&#xD;
&#xD;
               -  Cohort E: KRAS G12D mutation&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  Amenable to biopsy&#xD;
&#xD;
          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             scale&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participating in medical research not compatible with this study&#xD;
&#xD;
          -  Have not discontinued or recovered from previous treatments for cancer&#xD;
&#xD;
          -  Have a significant cardiac condition&#xD;
&#xD;
          -  Have untreated brain metastases&#xD;
&#xD;
          -  Have a primary brain tumor&#xD;
&#xD;
          -  Have a serious concomitant disorder&#xD;
&#xD;
          -  Unable to swallow or digest pills&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Concomitant medications or substances that are strong inhibitors/inducers of&#xD;
             CYP3A.Study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill Kremer, MD</last_name>
    <phone>609-250-7336</phone>
    <email>clinicaltrialinfo@taihooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Cedex</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>AKT inhibitor</keyword>
  <keyword>RSK inhibitor</keyword>
  <keyword>S6K inhibitor</keyword>
  <keyword>kinase inhibitor</keyword>
  <keyword>phase I</keyword>
  <keyword>phase 1</keyword>
  <keyword>NF1 mutation</keyword>
  <keyword>endocrine therapy resistance</keyword>
  <keyword>PTEN loss</keyword>
  <keyword>PTEN mutation</keyword>
  <keyword>KRAS G12C</keyword>
  <keyword>KRAS G12D</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

